Introduction
============

Colorectal cancer (CRC) is one of the most common malignant tumors and one of the most serious health problems worldwide ([@b1-ol-0-0-10010]). In China, the morbidity and mortality of CRC are both ranked fifth for all cancer types, responsible for 191,000 cancer-associated cases of mortality in 2015 ([@b2-ol-0-0-10010],[@b3-ol-0-0-10010]).

The diagnosis of CRC at an early stage is crucial to enhance the success of treatment approaches. However, the detection and management of CRC is challenging due to the variable nature of the disease ([@b4-ol-0-0-10010]). To the best of our knowledge, there are no reliable predictors of CRC development or rate of progression and the diagnosis of CRC is inadequate. Effective systems to predict the occurrence and aggression of this malignancy are urgently required ([@b5-ol-0-0-10010]). Previously, Saghapouret and Sehhati ([@b6-ol-0-0-10010]) used a logistic regression model and artificial neural networks (ANNs) as two nonlinear models to establish a two-stage hybrid modeling procedure for prediction of metastasis in advanced CRC. Additionally, Chen *et al* ([@b7-ol-0-0-10010]) developed a proteomic approach for the simultaneous detection and analysis of multiple proteins to distinguish individuals with CRC from healthy individuals.

ANNs are a family of models inspired by biological neural networks that are used to estimate functions that depend on a large number of generally unknown inputs ([@b8-ol-0-0-10010],[@b9-ol-0-0-10010]). ANNs constitute a class of flexible nonlinear models designed to mimic biological neural systems ([@b10-ol-0-0-10010]). ANNs are generally presented as systems of interconnected neurons that exchange messages with each other ([@b10-ol-0-0-10010]). Each connection has a numerical weight that can be adjusted based on experience, making ANNs adaptive to inputs and capable of learning ([@b10-ol-0-0-10010]). ANNs have been applied in many different areas and employed to solve medical diagnostic problems ([@b10-ol-0-0-10010]).

ANN is a mathematical and computational method that has been applied for diagnosis and prognosis prediction in several cancer types. Previously, this method has achieved higher sensitivity and specificity compared with traditional procedures ([@b11-ol-0-0-10010]--[@b13-ol-0-0-10010]). Recently, Peng *et al* ([@b14-ol-0-0-10010]) established a scoring system based on an ANN model which could better predict the long-term prognosis for patients with stage IIA colon cancer following radical surgery and screen out individuals at high risk of further aggressive progression. This study identified that decreased expression of *TGFBR2* and increased expression of *β-catenin, MAPK, TGF-β* and *pin1* may be predictive of a poor 10-year survival outcome.

The aim of the current study was to use ANN to build multiple CRC diagnosis models based on a dataset from The Cancer Genome Atlas (TCGA). The diagnosis models included: Cancer/Normal, M0/M1 (M0, without distant metastasis; M1, with distant metastasis), carcinoembryonic antigen (CEA) \<5/≥5 µg/l and Clinical stage I--II/III--IV. The models were generated to help clinicians diagnose patients with CRC, predict the postoperative outcome and screen high-risk prognostic subgroups.

Materials and methods
=====================

### Data collection

The mRNA expression data used in the current study was downloaded from TCGA (<https://cancergenome.nih.gov/>). The publically available dataset contained relatively large and diverse CRC RNA-seq expression data, with a total of 633 samples ([@b15-ol-0-0-10010]). Samples in which the respective clinical data were missing were deleted. A total of 328 samples were used in the current study. The dataset used in the Cancer/Normal contained 287 CRC samples and 41 healthy colorectal samples and M0/M1 models contained 189 M0 samples and 39 M1 samples. The database was filtered according to CEA classification and clinical stage for the CEA and Clinical stage models. Detailed information regarding the size of the relevant datasets is presented in [Table I](#tI-ol-0-0-10010){ref-type="table"}.

### Genetic algorithm (GA)

A GA is an optimization method used to identify the best solution to a problem by applying Darwin\'s evolution hypothesis and different genetic functions, including crossover and mutation ([@b16-ol-0-0-10010],[@b17-ol-0-0-10010]). GA was proposed by John Holland in the early 1970s ([@b18-ol-0-0-10010]). Compared to traditional optimization and search procedures, GA is a stochastic method used to solve optimization problems, particularly when there is little or no prior knowledge about the process to be controlled ([@b19-ol-0-0-10010],[@b20-ol-0-0-10010]). In the current study, GA was used as a robust nonlinear statistical method for variable selection. The feature genes selected by GA were used as numerical encoded parameters to denote cancerous, metastatic or healthy samples.

### Mean impact value (MIV)

MIV is considered to be one of the best indicators to evaluate the impact of input variables for neural cells in a neural network ([@b21-ol-0-0-10010]). Each input variable of the training samples, comprising of the 171 samples used for model 2 generation ([Table II](#tII-ol-0-0-10010){ref-type="table"}), was increased and decreased by 10% to create two new samples for the simulation function. Then the mean of the difference between values of simulation was calculated to provide the variable MIV. A well-trained neural network model based on MIV is theoretically capable of selecting the most important gene ([@b22-ol-0-0-10010]).

### ANNs: Back propagation (BP) and learning vector quantization (LVQ) models

In the current study, two types of ANN were used to build multiple diagnosis models: BP and LVQ. The BP neural network includes three layers: An input layer, a hidden layer and an output layer. The first layer has input neurons, which send data via synapses to a hidden layer of neurons, which have synapses to the third layer of output neurons ([@b9-ol-0-0-10010],[@b23-ol-0-0-10010]). The LVQ neural network was a method of training neural networks for pattern classification ([@b24-ol-0-0-10010],[@b25-ol-0-0-10010]). This network architecture includes the input layer, representing the space of inputs in the X dimension, the competition layer, which models the space of the inputs, and the output layer, in which decisions are made. In the current study, both algorithm programs were created using Matlab software (version 2010b; MathWorks, Natick, MA, USA).

### Evaluation of diagnosis models

The overall performance of the four models was evaluated by two distinct approaches: Predictive accuracy (ACC) and the area under the curve (AUC) of a receiver operating characteristic (ROC) curve for an independent dataset test. The stability of the models was evaluated using a 10-fold cross-validation test ([@b26-ol-0-0-10010]). ACC was defined as follows: ACC=(∑TP+TN)/N, where TP was the true positive, TN was the true negative and N was the total number of predicted samples.

The ability of a test to identify true positives and negatives in a dataset was measured by sensitivity and specificity as follows ([@b27-ol-0-0-10010]): Sensitivity = TP/(TP+FN) and specificity = TN/(TN+FP), where FN was the false negative and FP was the false positive.

An ROC curve demonstrates the efficacy of a test by identifying both the sensitivity and specificity for different cutoff points ([@b27-ol-0-0-10010]). ROC curve analysis was performed with R software (version 3.2.0; <http://www.r-project.org/>). The most frequently used criterion for comparing multiple ROC curves is the AUC, which can range from 0.5 (poor performance of prediction model/no discrimination) to 1.0 (ideal performance of prediction model/high discrimination) ([@b28-ol-0-0-10010]).

For 10-fold cross-validation testing, the dataset was randomly divided into 10 sets, nine of which were used to set the parameters of the predictive algorithm. ACC of the algorithm was then evaluated against the remaining set. This procedure was repeated 10 times before the sensitivity and specificity against different parameters were calculated by an ROC curve for 10 test datasets.

Results and Discussion
======================

### Feature gene selection

The CRC mRNA expression data from TCGA was divided into four different groups: Cancer/Normal (model 1), M0/M1 (model 2), CEA \<5/≥5 (model 3) and Clinical stage I--II/III--IV (model 4). A flow chart outlining the feature genes selection method is presented in [Fig. 1](#f1-ol-0-0-10010){ref-type="fig"}. Briefly, P-values and ratio values were calculated for all candidate genes by performing a t-test between every two groups using Excel 2007 (Microsoft Corporation, Redmond, WA, USA). Genes were selected with P\<0.05 and ratio \>2 for further analysis. The number of genes passing this first selection criteria for model 1, 2, 3 and 4 were 106, 80, 30 and 16, respectively. For selection of the most important genes, GA was run 1,000 times with different initial population sets. A population of good models was obtained. These genes were used to construct diagnosis models using the BP and LVQ techniques. Six, 17, 14 and three feature genes were selected to build models 1, 2, 3 and 4, respectively. Gene selection information is presented in [Tables II](#tII-ol-0-0-10010){ref-type="table"} and [III](#tIII-ol-0-0-10010){ref-type="table"}.

### Cancer/normal diagnosis model

Using the GA method, six feature genes (upregulated: *CPNE7*; downregulated: *MT1M, ATP1A2, ALPI, LOC646627* and *TMEM72*) were obtained to create the Cancer/Normal diagnosis model.

Here, the TCGA dataset was divided into a training set containing 246 samples that was used for model generation and a test set with 82 samples that was used to evaluate the model. The ACC and AUC of the training sets and test sets are presented in [Table IV](#tIV-ol-0-0-10010){ref-type="table"}. [Fig. 2A](#f2-ol-0-0-10010){ref-type="fig"} presents the ROC for the Cancer/Normal diagnosis model. The ACC and AUC were 100% and 1.000, respectively, for both the training set and the test set. AUC was applied to quantify the comprehensive performance of the prediction model. Therefore, the aforementioned statistical data indicated that the proposed Cancer/Normal diagnosis model exhibited a good ability to predict patients with cancer compared with healthy individuals.

The stability of the model was evaluated using a 10-fold cross-validation test and the results are presented in [Table V](#tV-ol-0-0-10010){ref-type="table"}. The ACC values of the Cancer/Normal diagnosis model in all 10 tests were in the range 93.75--99.39% and the sensitivity values were all 1.0000, suggesting that the Cancer/Normal diagnosis model has promising reliability and efficacy to identify cancer tissues against different test datasets.

### M0/M1 diagnosis model

M0 represents CRC without distant metastasis, while M1 represents CRC with distant metastasis. Distant metastasis is the main cause of cancer-associated cases of mortality for patients with CRC ([@b29-ol-0-0-10010]). The common organs for CRC distant metastasis are the liver and lung ([@b30-ol-0-0-10010]). As a result, M1 indicates a high risk of poor prognosis ([@b31-ol-0-0-10010]).

Following establishment of the BP diagnosis model to distinguish between cancer patients and healthy patients, the LVQ neural network was used to develop the M0/M1 diagnosis model with a training set of 171 samples, based on 17 feature genes selected by the MIV method (downregulated: *ALPPL2, ALPP, CACNG4, CAMK2B, DLX3, FREM2, GPR81, HEPHL1, KRT6A, LOC100133545, LOC440173, MAP7D2, MSLN, PSCA, SCEL, SLC14A1* and *SLC15A1*). The test set consisted of 57 samples.

As presented in [Table IV](#tIV-ol-0-0-10010){ref-type="table"} and [Fig. 2B](#f2-ol-0-0-10010){ref-type="fig"}, the ACC of the training set in the LVQ model was 87.14% and the AUC was 0.670. The ACC of the test set was 92.98% and the AUC was 0.855. The AUC value is an indicator of the efficacy of the diagnosis model; an AUC close to 1.0 indicates a high overall efficacy of the test. The test set of M0/M1 diagnosis model had an AUC of approximately 0.9, suggesting that it had a relatively high ability to identify the distant metastasis tissues against the tissues without distant metastasis. The statistical data of the test set indicated that the M0/M1 diagnosis model had the ability to predict patients with and without metastasis.

ACC values for the LVQ M0/M1 diagnosis model in all 10-fold cross-validation tests were in the range 80.58--88.24% and the sensitivity was in the range 0.9286--1.0000 ([Table IV](#tIV-ol-0-0-10010){ref-type="table"}). These results verified that the M0/M1 diagnosis model had a good statistical significance.

### CEA \<5/≥5 diagnosis model

CEA is an immunoglobulin cell adhesion molecule that is considered to be a marker for CRC ([@b32-ol-0-0-10010]). Previously, Spindler *et al* ([@b33-ol-0-0-10010]) reported that elevated preoperative CEA is a risk factor for aggressive tumor biology and poor prognosis for patients with CRC. CEA was also identified as an independent factor for shorter relapse-free survival and shorter overall survival (OS). Furthermore, elevated preoperative CEA has also been demonstrated to not only improve staging of CRC, but also guide adjuvant chemotherapy ([@b34-ol-0-0-10010]). Therefore, it is important to develop a CEA \<5/≥5 diagnosis model to improve diagnosis and therapy for patients with CRC.

The BP neural network was used to develop a CEA \<5/≥5 diagnosis model with a training set of 92 samples which contained 60 CEA \<5 and 32 CEA ≥5 samples based on 14 feature genes (upregulated: *ELF5, FABP4, GNG4* and *SVOPL*; downregulated: *ADH6, AHSG, CCL25, CPLX2, DEFA5, DKK4, EMX1, IGFL2, NOS2* and *TNFRSF6B*) selected by the GA method. The TCGA test set contained 30 samples (19 CEA \<5 and 11 CEA ≥5 samples).

The CEA \<5/≥5 diagnosis model had a good ability to predict patients with CEA \<5/≥5 in the training set and the test set. As presented in [Table IV](#tIV-ol-0-0-10010){ref-type="table"} and [Fig. 2C](#f2-ol-0-0-10010){ref-type="fig"}, the ACC for the training set was 100% and the AUC was 1.000. The ACC for the test set was 80% and the AUC was 0.8708. These statistical data indicate that the test set accuracy of the CEA \<5/≥5 model is \>80%.

The ACC values of the CEA \<5/≥5 diagnosis model in all 10-fold cross-validation tests were in the range 67.21--92.31% and the sensitivity values were in the range 0.7091--1.0000 ([Table V](#tV-ol-0-0-10010){ref-type="table"}). This demonstrates that the accuracy and sensitivity ranges of the training set are relatively large but it still has ACC \>67.21%, sensitivity \>0.7091. Demonstrating that the model has ability to diagnose disease.

### Clinical stage I--II/III--IV diagnosis model

The clinical stage of disease is an indicator of prognosis for patients with CRC. Clinical stage I--II is considered early stage, while clinical stage III--IV is considered to be late stage ([@b35-ol-0-0-10010],[@b36-ol-0-0-10010]).

The current study generated a clinical stage I--II/III--IV diagnosis model using the BP neural network to assist with CRC diagnosis. A BP neural network was used to develop the model with a training set containing 208 samples and a test set containing 69 samples based on three feature genes (downregulated: *LY6G6D, PALM3* and *PRKAA2*) selected by the GA method.

As presented in [Table IV](#tIV-ol-0-0-10010){ref-type="table"} and [Fig. 2D](#f2-ol-0-0-10010){ref-type="fig"}, the clinical stage I--II/III--IV diagnosis model training set had an ACC of 100% and an AUC of 1.0000. The ACC of the test set was 65.22% and the AUC was 0.6419. Meanwhile, the ACC values of this diagnosis model in all 10-fold cross-validation tests were in the range 59.13--68.85% and the sensitivity values were in the range 0.6017--0.6585 ([Table V](#tV-ol-0-0-10010){ref-type="table"}). This result indicates that although the training set for the Clinical stage I--II/III--IV diagnosis model has a high accuracy, the model is unreliable as the accuracy of the test set is only 65.22%.

### Survival analysis

Kaplan-Meier analysis with a log-rank test was used to determine OS of patients in the four diagnosis models. According to the results of these models, Kaplan-Meier survival curves of overall survival are presented in [Fig. 3](#f3-ol-0-0-10010){ref-type="fig"} (training set) and [Fig. 4](#f4-ol-0-0-10010){ref-type="fig"} (test set).

The healthy tissue and tumor tissue originated from the same sample, therefore, these paired samples have the same sample number and OS time so only one OS curve can be presented in [Figs. 3A](#f3-ol-0-0-10010){ref-type="fig"} and [4A](#f4-ol-0-0-10010){ref-type="fig"}. [Fig. 3B-D](#f3-ol-0-0-10010){ref-type="fig"} demonstrates significant differences in the OS between patients in the M0 and M1 groups (P=0.002; [Fig. 3B](#f3-ol-0-0-10010){ref-type="fig"}), CEA \<5 and CEA ≥5 groups (P=0.020; [Fig. 3C](#f3-ol-0-0-10010){ref-type="fig"}), and stage I--II and III--IV groups (P=0.001; [Fig. 3D](#f3-ol-0-0-10010){ref-type="fig"}).

By comparing the Kaplan-Meier survival curve for the test set to OS ([Fig. 4A](#f4-ol-0-0-10010){ref-type="fig"}), it can be concluded that the Cancer/Normal diagnosis model was successfully established. Furthermore, the current study effectively distinguished cancer samples into a favorable and unfavorable diagnosis group according to their M0/M1 and CEA index. As demonstrated in [Fig. 4B and C](#f4-ol-0-0-10010){ref-type="fig"}, a significant difference was identified in the OS rates of patients in the M1 and CEA ≥5 groups compared with those in the M0 and CEA ≥5 groups ([Fig 4B](#f4-ol-0-0-10010){ref-type="fig"}, P=0.002; [Fig. 4C](#f4-ol-0-0-10010){ref-type="fig"}, P=0.038).

As illustrated in [Fig. 4D](#f4-ol-0-0-10010){ref-type="fig"}, no statistically significant difference was identified in the OS time of the stage I--II groups compared with the stage III--IV groups (P=0.375). [Fig. 4D](#f4-ol-0-0-10010){ref-type="fig"} also demonstrates that there was no significant difference in the OS rate of the two groups after 100 months. Therefore, the clinical stage I--II/III--IV model is not suitable for predicting prognosis of patients with CRC.

In conclusion, the current study established multiple novel diagnosis models for human CRC based on TCGA data using the ANN method. Feature genes were selected by GA and MIV methods, which represent characteristics of tumor and healthy samples that were used to generate the diagnosis models. Analysis demonstrated that the BP and LVQ models have strong predictive abilities with high ACC and AUC values in both the training and test sets, as well as robust stability, with notable accuracy and sensitivity values determined by 10-fold cross-validation. The M0/M1 and CEA \<5/≥5 diagnosis models demonstrated a high ability to predict patient prognosis. The Cancer/Normal, M0/M1, CEA \<5/≥5 and Clinical stage diagnosis models created in the current study, used a variety of artificial intelligence algorithms combined with an RNA-seq dataset to assist with human CRC diagnosis and postoperative outcome prediction.
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###### 

Datasets used in the four diagnosis models.

  Datasets                 Cancer/normal, n   M0/M1, n   CEA \<5/≥5, n   Clinical stage I--II/III--IV, n
  ------------------------ ------------------ ---------- --------------- ---------------------------------
  TCGA_colorectal cancer   287/41             189/39     79/43           155/101

TCGA, The Cancer Genome Atlas; M0, without distant metastasis; M1, with distant metastasis; CEA, carcinoembryonic antigen.

###### 

Number of samples used in training sets and test sets.

                        Diagnosis model                    
  -------------- ------ ----------------- -------- ------- --------
  Training set   246    215/31            --       --      --
  Test set         82   72/10             --       --      --
  Training set   171    --                140/31   --      --
  Test set         57   --                49/8     --      --
  Training set     92   --                --       60/32   --
  Test set         30   --                --       19/11   --
  Training set   208    --                --       --      118/90
  Test set         69   --                --       --      37/32

M0, without distant metastasis; M1, with distant metastasis; CEA, carcinoembryonic antigen.

###### 

Diagnostic genes used in diagnosis models.

  Diagnosis model   Gene symbol    mRNA description                                          Ratio    Regulation
  ----------------- -------------- --------------------------------------------------------- -------- ------------
  Cancer/normal     MT1M           Metallothionein 1M                                        57.35    Down
  Cancer/normal     ATP1A2         ATPase Na^+^/K^+^ Transporting Subunit Alpha 2            45.00    Down
  Cancer/normal     ALPI           Alkaline Phosphatase, Intestinal                          43.49    Down
  Cancer/normal     LOC646627      Uncharacterized LOC646627                                 43.23    Down
  Cancer/normal     TMEM72         Transmembrane Protein 72                                  34.31    Down
  Cancer/normal     CPNE7          Copine 7                                                  33.87    Up
  M0/M1             ALPPL2         Alkaline Phosphatase, Placental Like 2                      2.08   Down
  M0/M1             ALPP           Alkaline Phosphatase, Placental                             2.35   Down
  M0/M1             CACNG4         Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 4     2.60   Down
  M0/M1             CAMK2B         Calcium/Calmodulin Dependent Protein Kinase II Beta         2.30   Down
  M0/M1             DLX3           Distal-Less Homeobox 3                                      2.87   Down
  M0/M1             FREM2          FRAS1 Related Extracellular Matrix Protein 2                2.52   Down
  M0/M1             GPR81          Hydroxycarboxylic Acid Receptor 1                           2.14   Down
  M0/M1             HEPHL1         Hephaestin Like 1                                           2.25   Down
  M0/M1             KRT6A          Keratin 6A                                                  2.24   Down
  M0/M1             LOC100133545   MRPL23 antisense RNA 1                                      2.62   Down
  M0/M1             LOC440173      Uncharacterized LOC440173                                   2.03   Down
  M0/M1             MAP7D2         MAP7 Domain Containing 2                                    2.21   Down
  M0/M1             MSLN           Mesothelin                                                  2.05   Down
  M0/M1             PSCA           Prostate Stem Cell Antigen                                  2.19   Down
  M0/M1             SCEL           Sciellin                                                    2.39   Down
  M0/M1             SLC14A1        Solute Carrier Family 14 Member 1 (Kidd Blood Group)        3.47   Down
  M0/M1             SLC15A1        Solute Carrier Family 15 Member 1                           2.08   Down
  CEA \<5/≥5        ADH6           Alcohol Dehydrogenase 6 (Class V)                           2.17   Down
  CEA \<5/≥5        AHSG           Alpha-2-HS-Glycoprotein                                     2.05   Down
  CEA \<5/≥5        CCL25          C-C Motif Chemokine Ligand 25                               3.34   Down
  CEA \<5/≥5        CPLX2          Complexin 2                                                 2.36   Down
  CEA \<5/≥5        DEFA5          Defensin Alpha 5                                            4.40   Down
  CEA \<5/≥5        DKK4           Dickkopf WNT Signaling Pathway Inhibitor 4                  2.25   Down
  CEA \<5/≥5        ELF5           E74 Like ETS Transcription Factor 5                         2.39   Up
  CEA \<5/≥5        EMX1           Empty Spiracles Homeobox 1                                  3.04   Down
  CEA \<5/≥5        FABP4          Fatty Acid Binding Protein 4                                2.19   Up
  CEA \<5/≥5        GNG4           G Protein Subunit Gamma 4                                   2.58   Up
  CEA \<5/≥5        IGFL2          IGF Like Family Member 2                                    2.08   Down
  CEA \<5/≥5        NOS2           Nitric Oxide Synthase 2                                     2.31   Down
  CEA \<5/≥5        SVOPL          SVOP Like                                                   2.07   Up
  CEA \<5/≥5        TNFRSF6B       Tumor Necrosis Factor Receptor Superfamily 6b               2.11   Down
  Clinical stage    LY6G6D         Lymphocyte Antigen 6 Complex, Locus G6D                     2.01   Down
  I--II/III--IV                                                                                       
  Clinical stage    PALM3          Paralemmin 3                                                2.23   Down
  I--II/III--IV                                                                                       
  Clinical stage    PRKAA2         Protein Kinase AMP-Activated Catalytic Subunit Alpha 2      2.14   Down
  I--II/III--IV                                                                                       

M0, without distant metastasis; M1, with distant metastasis; CEA, carcinoembryonic antigen.

###### 

Diagnosis model testing results.

  Diagnosis model                Use            ACC, %    AUC
  ------------------------------ -------------- --------- --------
  Cancer/Normal                  Training set   100.00    1.0000
  Cancer/Normal                  Test set       100.00    1.0000
  M0/M1                          Training set     87.14   0.6700
  M0/M1                          Test set         92.98   0.8550
  CEA \<5/≥5                     Training set   100.00    1.0000
  CEA \<5/≥5                     Test set         80.00   0.8708
  Clinical stage I--II/III--IV   Training set   100.00    1.0000
  Clinical stage I--II/III--IV   Test set         65.22   0.6419

M0, without distant metastasis; M1, with distant metastasis; CEA, carcinoembryonic antigen; ACC, accuracy; AUC, area under curve.

###### 

10-fold cross validation of diagnosis model TCGA training sets.

          Cancer/normal   M0/M1    CEA \<5/≥5   Clinical stage I--II/III--IV                              
  ------- --------------- -------- ------------ ------------------------------ -------- -------- -------- --------
  10-1    0.9375          1.0000   0.8824       1.0000                         0.9231   1.0000   0.6000   0.6364
  10-2    0.9692          1.0000   0.8824       1.0000                         0.8000   0.9375   0.6829   0.6087
  10-3    0.9796          1.0000   0.8431       0.9762                         0.7568   0.8750   0.6885   0.6176
  10-4    0.9847          1.0000   0.8088       0.9496                         0.7551   0.8438   0.6707   0.6304
  10-5    0.9878          1.0000   0.8118       0.9429                         0.7377   0.7750   0.6602   0.6552
  10-6    0.9898          1.0000   0.8058       0.9286                         0.6986   0.7234   0.6452   0.6429
  10-7    0.9913          1.0000   0.8083       0.9388                         0.6744   0.7091   0.6414   0.6585
  10-8    0.9924          1.0000   0.8102       0.9464                         0.6735   0.7143   0.6024   0.6170
  10-9    0.9923          1.0000   0.8117       0.9524                         0.6909   0.7324   0.5936   0.6038
  10-10   0.9939          1.0000   0.8187       0.9571                         0.6721   0.7215   0.5913   0.6017

M0, without distant metastasis; M1, with distant metastasis; CEA, carcinoembryonic antigen; ACC, accuracy; Sen, sensitivity.
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